Early cranial radiotherapy may improve outcomes for patients with EGFR-mutant NSCLC and limited brain metastases
Eight-year ADAURA update shows sustained overall survival benefit with adjuvant osimertinib in resected EGFR-mutated NSCLC
Zipalertinib plus chemotherapy significantly extends progression-free survival in first-line EGFR exon 20 insertion-positive NSCLC
In the PAPILLON study, first-line amivantamab-chemotherapy demonstrates the longest overall survival reported for EGFR exon 20 insertion-positive advanced NSCLC
Phase 1 study supports recommended phase 3 dose for investigational EGFR x HER3 antibody-drug conjugate in EGFR-mutated lung cancer
Surgery for locally advanced stage IIIB (T4N2) EGFR-mutated lung adenocarcinoma in the era of targeted therapy: a case report - EurekAlert!
Osimertinib with or without chemotherapy in advanced non–small cell lung cancer with EGFR and concurrent TP53 mutations - EurekAlert!
26 Years of development of EGFR-TKIs for non-small cell lung cancer: Clinical application and resistance research progress - EurekAlert!
COCOON trial shows proactive skin care can halve dermatologic toxicity in EGFR-mutant NSCLC - EurekAlert!
Unmasking a hidden driver of glioma: CHKA teams up with EGFR to ignite the MAPK pathway - EurekAlert!
Efficacy and safety of immune checkpoint inhibitors in EGFR-mutant NSCLC patients with EGFR-TKI resistance: an updated systematic review and meta-analysis - EurekAlert!
Discordance in creatinine- and cystatin C–based eGFR and clinical outcomes - EurekAlert!
Chemotherapy combination boosts overall survival in patients with EGFR-mutant non-small cell lung cancer - EurekAlert!
Surgery after EGFR TKI shows promise in prolonging progression-free survival in metastatic NSCLC - EurekAlert!
BMS-986504 demonstrates durable responses in MTAP-deleted NSCLC, including EGFR and ALK-positive tumors - EurekAlert!
Aumolertinib plus chemotherapy improves progression-free survival in NSCLC with EGFR and concomitant tumor suppressor genes: ACROSS 2 phase III study - EurekAlert!
FLAURA2 trial shows osimertinib plus chemotherapy improves overall survival in eGFR-mutated advanced NSCLC - EurekAlert!
Ivonescimab plus chemotherapy improves progression-free survival in patients with EGFR+ NSCLC following 3rd-generation EGFR-TKI therapy - EurekAlert!
Iza-Bren in combination with osimertinib shows 100% response rate in EGFR-mutated NSCLC, phase II study finds - EurekAlert!
COMPEL study shows continuing osimertinib treatment through progression with the addition of chemotherapy improves progression-free survival in EGFR-mutated NSCLC - EurekAlert!
